With six treatments in the clinical phase, Leo Pharma can look forward to another heavy year for development
In 2020, Leo Pharma is rearming itself in order to massively increase the research and development budget. The aim is to accelerate the development of new drugs, including the company's big hope: eczema drug tralokinumab.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Although biological eczema drug tralokinumab seems to get all of the attention, Leo Pharma has five other drugs in its clinical development pipeline.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
